These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Correlations of 18F-FDG and 18F-FLT uptake on PET with Ki-67 expression in patients with lung cancer: a meta-analysis. Shen G; Ma H; Pang F; Ren P; Kuang A Acta Radiol; 2018 Feb; 59(2):188-195. PubMed ID: 28475024 [TBL] [Abstract][Full Text] [Related]
44. Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients. Johnbeck CB; Knigge U; Langer SW; Loft A; Berthelsen AK; Federspiel B; Binderup T; Kjaer A J Nucl Med; 2016 Dec; 57(12):1851-1857. PubMed ID: 27469355 [TBL] [Abstract][Full Text] [Related]
45. A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma. Herrmann K; Buck AK; Schuster T; Rudelius M; Wester HJ; Graf N; Scheuerer C; Peschel C; Schwaiger M; Dechow T; Keller U J Nucl Med; 2011 Dec; 52(12):1898-902. PubMed ID: 22065875 [TBL] [Abstract][Full Text] [Related]
46. Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial. Zanoni L; Broccoli A; Lambertini A; Pellegrini C; Stefoni V; Lodi F; Fonti C; Nanni C; Zinzani PL; Fanti S Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1661-1671. PubMed ID: 31102000 [TBL] [Abstract][Full Text] [Related]
47. Clinical relevance of imaging proliferative activity in lung nodules. Buck AK; Hetzel M; Schirrmeister H; Halter G; Möller P; Kratochwil C; Wahl A; Glatting G; Mottaghy FM; Mattfeldt T; Neumaier B; Reske SN Eur J Nucl Med Mol Imaging; 2005 May; 32(5):525-33. PubMed ID: 15599526 [TBL] [Abstract][Full Text] [Related]
48. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150 [TBL] [Abstract][Full Text] [Related]
49. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer. Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204 [TBL] [Abstract][Full Text] [Related]
50. Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions. Beauregard JM; Giraudet AL; Aide N; Hofman MS; Blum R; Drummond E; Roselt P; Hicks RJ Nucl Med Commun; 2013 Jun; 34(6):521-6. PubMed ID: 23542911 [TBL] [Abstract][Full Text] [Related]
51. Usefulness of 3'-deoxy-3'-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer. Kishino T; Hoshikawa H; Nishiyama Y; Yamamoto Y; Mori N J Nucl Med; 2012 Oct; 53(10):1521-7. PubMed ID: 22872738 [TBL] [Abstract][Full Text] [Related]
52. Imaging proliferation in human leukemia-tumor bearing mice with (18)F-FLT: Comparison with (18)F-FDG PET. Lu L; Jiang L; Guan H; Gao Y; Lu H Hell J Nucl Med; 2012; 15(3):206-9. PubMed ID: 23106052 [TBL] [Abstract][Full Text] [Related]
54. FLT PET/CT Is Better Than FDG PET/CT in Differentiating Benign From Malignant Pancreatobiliary Lesions. Vineeth Kumar PM; Verma GR; Mittal BR; Agrawal K; Gupta R; Kochhar R; Singh V; Kaman L; Singh R Clin Nucl Med; 2016 May; 41(5):e244-50. PubMed ID: 26914562 [TBL] [Abstract][Full Text] [Related]
55. F-18 fluorodeoxyglucose and F-18 fluorothymidine positron emission tomography/computed tomography imaging in a case of neurosarcoidosis. Kim SK; Im HJ; Kim W; Kim TS; Hwangbo B; Kim HJ Clin Nucl Med; 2010 Feb; 35(2):67-70. PubMed ID: 20090446 [TBL] [Abstract][Full Text] [Related]
56. [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer. Been LB; Hoekstra HJ; Suurmeijer AJ; Jager PL; van der Laan BF; Elsinga PH Oral Oncol; 2009 Dec; 45(12):e211-5. PubMed ID: 19692292 [TBL] [Abstract][Full Text] [Related]
57. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Apisarnthanarax S; Alauddin MM; Mourtada F; Ariga H; Raju U; Mawlawi O; Han D; Bornmann WG; Ajani JA; Milas L; Gelovani JG; Chao KS Clin Cancer Res; 2006 Aug; 12(15):4590-7. PubMed ID: 16899606 [TBL] [Abstract][Full Text] [Related]
58. Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined Sachpekidis C; Goldschmidt H; Kopka K; Kopp-Schneider A; Dimitrakopoulou-Strauss A EJNMMI Res; 2018 Apr; 8(1):28. PubMed ID: 29633046 [TBL] [Abstract][Full Text] [Related]
59. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET. Kameyama R; Yamamoto Y; Izuishi K; Takebayashi R; Hagiike M; Murota M; Kaji M; Haba R; Nishiyama Y Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):382-8. PubMed ID: 18985344 [TBL] [Abstract][Full Text] [Related]